```text
Wiki Article
Abciximab (C7E3, 143653-53-6): A Research Reagent Overview
Abciximab, also identified as C7E3 or bearing the CAS number 143653-53-6, functions as a valuable laboratory substance extensively utilized in cardiovascular investigations. This Fab fragment specifically targets the glycoprotein IIb/IIIa receptor on platelets , blocking clot formation . Consequently , it's often applied as a method to explore the processes underlying thrombosis and to determine the effectiveness of Recombinant abciximab antiplatelet drugs . Supply is typically restricted to academic settings.
```
Abciximab Drug Research: Utilizing C7E3 Antibody and The 143653-53-6 Substance in Research Investigations
Ongoing research into abciximab, a antiplatelet agent, frequently utilizes the monoclonal antigen C7E3 and the substance identified as 143653-53-6. These materials are instrumental for analyzing abciximab's mechanism of action, evaluating its therapeutic effect in experimental conditions, and exploring potential indicators of therapeutic success. Continued exploration leveraging these precise reagents is expected to yield valuable information for enhancing clinical applications involving cardiovascular disease.
```text
C7E3 abciximab, also known as c7e3fragment, is a GPIIb/IIIa receptor antagonist widely utilized in scientific research. Its primary application lies in platelet aggregation studies, allowing investigators to probe the mechanisms underlying thrombosis and hemostasis. Researchers employ this agent to investigate the role of platelet activation in various disease models, including ischemia-reperfusion injury and inflammation. Beyond basic research, abciximab is increasingly used in developing novel antithrombotic therapies and evaluating their efficacy. Furthermore, studies exploring its potential to modulate vascular smooth muscle cell function and reduce intracranial bleeding are ongoing. The availability of c7e3 abciximab facilitates a deeper understanding of platelet-mediated processes and contributes to the advancement of translational medicine. }
```
```text
Investigating Scientific Opportunities with this Glycoprotein IIb/IIIa Inhibitor 143653-53-6 via C7E3
Recent work demonstrate that the drug (identified as 143653-53-6) presents significant scientific value, particularly when paired with C7E3. Preliminary findings indicated that this pairing might improve clinical responses in various heart-related contexts. Further investigation is directed on elucidating the specific mode of effect between the antiplatelet medication and C7E3, involving assessment of thrombocyte cohesion and blood vessel protection.
- Current research endeavors intend to refine dosing strategies.
- Laboratory models are were employed to further confirm such theories.
- Human assessments might be essential to completely assess therapeutic efficacy.
```
Abciximab (C7E3) for Research: Specifications and Details (143653-53-6)
Researchers seeking abciximab for experimental investigations should meticulously assess purity and defined specifications . Material 143653-53-6 is typically offered as a solid powder and detailed analytical documentation including verification by mass spectrometry , binding affinity assays, and endotoxin level testing is available. Ensure the manufacturer's certificate of analysis outlines defined ranges for contaminants and meets established quality assurance criteria .
Pharmaceutical-Grade Abciximab Details & Stock
Acquiring research-grade Abciximab, specifically referencing the molecule C7E3 and identified by the product number 143653-53-6, requires thorough consideration of its manufacturer. This agent is widely utilized in laboratory studies , particularly those focused on platelet clumping and thrombosis . Available sources offer this substance in varying volumes, typically ranging from g to substantial commercial supplies. Kindly advise reviewing the certificate of testing to verify purity and applicability for your specific application . Furthermore , ensure the stability date before obtaining to maintain ideal performance .
- Common Purity: >95%
- Keeping Conditions: -20°C and suitable conditions
- Application : Platelet Aggregation Suppression Studies